From Genetic Risk to Preventive Solutions
Cardiovascular diseases (CVDs) continue to be the leading cause of mortality globally and in Mexico. Heart attacks, strokes,…
Rivaroxaban or Combo Therapy: A Winner for All Ages? – Medscape
Rivaroxaban or Combo Therapy: A Winner for All Ages? Medscape Rivaroxaban Monotherapy Benefits Those with Atrial Fibrillation, Stable Coronary…
Low-Dose Colchicine May Help Stabilize Coronary Plaques
TOPLINE: The LoDoCo2 trial found a reduced cardiovascular risk with low-dose colchicine in patients with chronic coronary disease.…
What Else Can GLP-1 Drugs Do for Your Patients?
Glucagon-like peptide 1 (GLP-1) receptor agonists are transforming the treatment landscape for type 2 diabetes ( T2D) and…